Peptide Therapeutics Forum 2016 (Basel Life)

Peptide Therapeutics Forum 2016 (Basel Life)

In the framework of the Basel Life Science Week & MipTec Exhibition 2016, the two days “Peptide Therapeutics Forum 2016” focus on “early peptide discovery” and “development candidates for therapeutic peptides”.

Start Date 20.09.2016 - 09:15
Event End 21.09.2016 - 17:15
Location Congress Center Basel

In the framework of the Basel Life Science Week & MipTec Exhibition 2016, the two days “Peptide Therapeutics Forum 2016” focus on “early peptide discovery” and “development candidates for therapeutic peptides”. The first part highlights contributions of ligation chemistry to arrive at larger synthetic peptides/protein, recent insights in peptidic vaccine design, and news from venom drug discovery. Progress in peptide synthesis and case studies including generic half-life extension are foreseen for the second day. 

Flyer "Peptide Therapeutics Forum 2016"

Confirmed Speakers:

  • R. Liskamp, University of Glasgow UK, «Opportunities for chemical protein mimics in vaccine design»
  • M. Bachmann, Inselspital Bern CH, «Targeting peptides versus proteins by vaccination: size matters»
  • J-L. Reymond, University of Bern CH, «A Chemical Space Approach to Discover Novel Antimicrobial Peptides»
  • L. Rajendran, University of Zurich CH, «Lipidated peptides for cellular compartmentalization of beta-secretase inhibition»
  • E. Kitas, F. Hoffmann-La Roche, Basel CH, «Brain Shuttle targeting Antibody coupled to peptide-based payloads»
  • Dr. Peter White, Merck, Nottingham UK, «Recent advances in solid phase peptide synthesis»
  • O. Seitz, Humboldt University Berlin DE, «Enabling methods for the rapid total chemical synthesis of proteins»
  • Y.Kajihara, University of Osaka JP, «Chemical synthesis of homogeneous glycoprotein for elucidation of oligosaccharide functions»
  • P. Dawson, The Scripps Research Institute, La Jolla US, «Making connections in peptide chemistry»
  • R. Süssmuth, TU Berlin DE, «Chemical Biology of Peptide Natural Products - Structures, Syntheses and Bioactivities»
  • P. Alewood, University of Queensland, Brisbane AU, «Oxytocin Mimetics»
  • B. Olivera, US, «Therapeutic Potential of Conus Venom Peptides»
  • H. Kolmaar, TU Darmstadt DE, «Knottins and beyond: mono- and oligovalent constrained peptide Inhibitors for biomedical applications»
  • R. Bathgate, Florey Neuroscience Institutes AU, «The challenges of targeting RXFPI, the receptor for the heart failure drug candidate Relaxin-2, with peptide mimetic and small molecules»
  • Y-H. Song, BIND Therapeutics, Cambridge US, «Nanoencapsulation of peptide drugs for drug delivery: strategy, preparation, and applications»
  • V. Schellenberger, Amunix Mountainview US, «XTEN Protein Polymer for Half-Life Extension and Tumor Drug Delivery»

Contact:

T. Vorherr, Novartis Pharma AG, Basel CH 
E. Kitas, Roche Innovation Center, Basel CH 
R. Stocklin, Atheris SA, Geneva CH